Search results for "Recurrence"

showing 10 items of 1036 documents

Current challenges in metastasis: Disseminated and circulating tumor cells detection

2014

Metastatic dissemination of the primary tumor is responsible for the majority of cancer-related morbidity and mortality. Detection of disseminated tumor cells in the bone marrow and circulating tumor cells in the peripheral blood is associated with early metastatic recurrence in cancer. Circulating tumor cells (CTCs) shed from the site of disease in metastatic or primary tumor that can be recognized and enriched in the peripheral blood of cancer patients. The detection of rare circulating tumor cells (CTC) is an objective of numerous oncologists' researches. Circulating tumor cells have the potential to help to detect cancer recurrence at its earlier stage, determine therapy resistance befo…

Oncologymedicine.medical_specialtybusiness.industryImmunologyCancerGeneral MedicineDiseaseNeoplastic Cells Circulatingmedicine.diseasePrimary tumorMetastasisClinical trialmedicine.anatomical_structureCirculating tumor cellNeoplasmsInternal medicinemedicineHumansImmunology and AllergyBone marrowNeoplasm MetastasisNeoplasm Recurrence LocalStage (cooking)businessHuman Antibodies
researchProduct

Impact of Postoperative Complications on Survival and Recurrence After Resection of Colorectal Liver Metastases

2019

OBJECTIVE To study the effect of postoperative complications (POC) on overall survival (OS) and disease-free survival (DFS) after surgical resection of colorectal liver metastases (CRLM). SUMMARY BACKGROUND DATA Morbidity rates after liver resection can reach 45%. The negative impact of POC on oncologic outcomes has been reported in various types of cancer, especially colorectal. However, data on the consequences of POC after CRLM resection on long-term survival are scarce. METHODS Eligible studies examining the association between POC after CRLM resection and OS/DFS were sought using the PubMed and Web of Science databases. A random-effects model was used to calculate pooled effect estimat…

Oncologymedicine.medical_specialtymedicine.medical_treatmentSubgroup analysisResection03 medical and health sciencesPostoperative Complications0302 clinical medicineInternal medicinemedicineHepatectomyHumansSurvival rateSurvival analysisbusiness.industryLiver NeoplasmsHazard ratioCancermedicine.diseaseSurvival Rate030220 oncology & carcinogenesisMeta-analysis030211 gastroenterology & hepatologySurgeryNeoplasm Recurrence LocalHepatectomyColorectal NeoplasmsbusinessAnnals of Surgery
researchProduct

Mitotane Concentrations Influence Outcome in Patients With Advanced Adrenocortical Carcinoma

2020

Mitotane is the main option of treatment for advanced adrenocortical carcinoma (ACC). However, limited evidence is available regarding the impact of plasma mitotane levels on patient outcome. To address this question, we retrospectively analyzed patients with advanced ACC treated with mitotane for &ge

OncologymitotaneCancer Researchmedicine.medical_specialtyMultivariate analysisrecurrenceCombination therapyPrognosimedicine.medical_treatment030209 endocrinology & metabolismDiseaselcsh:RC254-282behavioral disciplines and activitiessurvivalArticle03 medical and health sciences0302 clinical medicineInternal medicinemedicineAdrenocortical carcinomaMitotaneIn patientadrenal cancerObjective responseadrenal cancer; mitotane; prognosis; recurrence; survivalChemotherapybusiness.industrylcsh:Neoplasms. Tumors. Oncology. Including cancer and carcinogensmedicine.diseaseOncology030220 oncology & carcinogenesisprognosisbusinessAdrenal cancer Mitotane Prognosis Recurrence Survivalmedicine.drug
researchProduct

Recurrent Ischemic Stroke and Bleeding in Patients With Atrial Fibrillation Who Suffered an Acute Stroke While on Treatment With Nonvitamin K Antagon…

2022

Background: In patients with atrial fibrillation who suffered an ischemic stroke while on treatment with nonvitamin K antagonist oral anticoagulants, rates and determinants of recurrent ischemic events and major bleedings remain uncertain. Methods: This prospective multicenter observational study aimed to estimate the rates of ischemic and bleeding events and their determinants in the follow-up of consecutive patients with atrial fibrillation who suffered an acute cerebrovascular ischemic event while on nonvitamin K antagonist oral anticoagulant treatment. Afterwards, we compared the estimated risks of ischemic and bleeding events between the patients in whom anticoagulant therapy was chan…

OralAdvanced and Specialized NursinghypertensionrecurrenceanticoagulantAdministration OralAnticoagulantsHemorrhageSettore MED/26Brain IschemiaStrokeRisk FactorsAdministrationAtrial FibrillationHumansSettore MED/26 - NeurologiaHuman medicineNeurology (clinical)Prospective StudiesCardiology and Cardiovascular MedicineAnticoagulants; atrial fibrillation; hypertension; ischemic stroke; recurrenceIschemic StrokeStroke
researchProduct

A multicenter observational study on the role of comorbidities in the recurrent episodes of benign paroxysmal positional vertigo

2014

Objective: Primary objective of this study was to find a statistical link between the most worldwide comorbidities affecting the elderly population (hypertension, diabetes, osteoarthrosis, osteoporosis and depression) and recurrent episodes of BPPV. Secondary objective was defining possible "groups of risk" for people suffering recurrent positional vertigo related to the presence of a well documented comorbidity. Methods: This was an observational, cross-sectional, multicenter, spontaneous, non-pharmacological study. The data of 1092 patients suffering BPPV evaluated in 11 different Departments of Otolaryngology, Otoneurology and Neurology, referring Centers for positional vertigo evaluatio…

OsteoarthrosisMalemedicine.medical_specialtyPediatricsAsiaNeurologyBenign paroxysmal positional vertigoOsteoporosisComorbidityOtolaryngologyElderlyRecurrenceRisk FactorsVertigoOsteoarthritisDiabetes Mellitusotorhinolaryngologic diseasesmedicineHumansBenign Paroxysmal Positional VertigoDepression (differential diagnoses)AgedRetrospective StudiesAged 80 and overDepressive Disorderbiologybusiness.industryDiabetesGeneral MedicineOdds ratioSouth AmericaBPPVmedicine.diseasebiology.organism_classificationComorbiditySemicircular CanalsEuropeCross-Sectional StudiesNeurologyOtorhinolaryngologyHypertensionVertigoPhysical therapyOsteoporosisFemaleSurgeryObservational studysense organsbusinessAuris Nasus Larynx
researchProduct

Multicentric, multifocal, and recurrent osteoid osteoma of the hip: first case report.

2019

Abstract Background Osteoid osteoma is a benign bone-forming tumour, which very unfrequently has multifocal or multicentric presentation. We report the first known case of a multicentric, multifocal and recurrent osteoid osteoma treated using radiofrequency ablation. Case presentation A 39-year-old man with two-year history of left hip pain was admitted at our Institution. The pain was more intense during the night and partially relieved by salicylates. Pelvis CT demonstrated two lytic lesions (8 and 7 mm, respectively) with surrounding sclerotic reactive bone, both with a central focal area of high attenuation, located in the femoral neck and along the anterior portion of the acetabulum, r…

Osteoid osteomamusculoskeletal diseasesAdultMalemedicine.medical_specialtylcsh:Diseases of the musculoskeletal systemRadiofrequency ablationBiopsyOsteoma OsteoidBone NeoplasmsCase Reportlaw.inventionLesion03 medical and health sciences0302 clinical medicineRheumatologylawMedicineHumansOrthopedics and Sports MedicineComputed tomographyPelvisFemoral neck030203 arthritis & rheumatology030222 orthopedicsRadiofrequency AblationHipmedicine.diagnostic_testbusiness.industryFemur NeckMagnetic resonance imagingAcetabulummedicine.diseaseAcetabulumMagnetic Resonance ImagingPosterior columnbody regionsmedicine.anatomical_structureTreatment OutcomeOsteoid osteomaRetreatmentRadiologylcsh:RC925-935medicine.symptomNeoplasm Recurrence LocalbusinessTomography X-Ray ComputedBMC musculoskeletal disorders
researchProduct

Is There a Role for Tertiary (TCR) and Quaternary (QCR) Cytoreduction in Recurrent Ovarian Cancer?

2015

BACKGROUND: The aim of the present study was to evaluate the efficacy of tertiary and quaternary cytoreduction in recurrent ovarian cancer patients. PATIENTS AND METHODS:Between January 1997 and December 2014, 53 patients were submitted to cytoreductive surgery for second and third ovarian cancer recurrence at our Unit. RESULTS:Median age at first diagnosis was 48 years (range=20-69). Forty-six patients (86.8%) underwent tertiary cytoreduction. At the time of surgery, isolated and diffuse disease was observed in 48 (90.6%) and 5 (9.4%) patients, respectively. Complete and optimal cytoreduction was obtained in 41 (77.5%) and in 1 (1.9%) patients, respectively. We did not observe any statisti…

Ovarian NeoplasmsAdultReoperationCytoreduction Surgical ProcedureMedicine (all)Ovarian NeoplasmTCR QCR cytoreductionRecurrent ovarian cancer; quaternary cytoreduction; tertiary cytoreduction; Adult; Aged; Cytoreduction Surgical Procedures; Female; Humans; Middle Aged; Neoplasm Recurrence; Local; Ovarian Neoplasms; Reoperation; Survival Analysis; Young Adultquaternary cytoreductionCytoreduction Surgical ProceduresMiddle AgedSurvival AnalysisYoung Adultovarian cancerSettore MED/40 - GINECOLOGIA E OSTETRICIAtertiary cytoreductionHumansFemaleSurvival AnalysiRecurrent ovarian cancerNeoplasm Recurrence Localquaternary cytoreduction; Recurrent ovarian cancer; tertiary cytoreduction; Medicine (all)AgedHuman
researchProduct

miR-205-5p-mediated downregulation of ErbB/HER receptors in breast cancer stem cells results in targeted therapy resistance

2015

AbstractThe ErbB tyrosine kinase receptor family has been shown to have an important role in tumorigenesis, and the expression of its receptor members is frequently deregulated in many types of solid tumors. Various drugs targeting these receptors have been approved for cancer treatment. Particularly, in breast cancer, anti-Her2/EGFR molecules represent the standard therapy for Her2-positive malignancies. However, in a number of cases, the tumor relapses or progresses thus suggesting that not all cancer cells have been targeted. One possibility is that a subset of cells capable of regenerating the tumor, such as cancer stem cells (CSCs), may not respond to these therapeutic agents. Accumula…

P63cancer stem cellsCancer ResearchReceptor ErbB-2oncogenesmedicine.medical_treatmentmedicine.disease_causeTargeted therapyERBB3Molecular Targeted TherapyDEATHErbB ReceptorsGene Expression Regulation NeoplasticNeoplastic Stem CellsFemaleOriginal Articlemedicine.drugCARCINOMAMIGRATIONCancer Stem Cells; Breast CancerImmunologyBreast NeoplasmsCancer Stem CellMIR-205miR-205-5pBiologyLapatinibcancer treatmentNOCellular and Molecular Neurosciencebreast cancerBreast cancerErbBCancer stem cellCell Line TumormedicineHumansSUPPRESSIONCell ProliferationMESENCHYMAL TRANSITIONtumorigenesis cancer treatment cancer stem cells miR-205-5p oncogenes breast cancerMICRORNA EXPRESSIONTumor Suppressor ProteinsLapatinibCell BiologyTrastuzumabmedicine.diseaseGENEMicroRNAstumorigenesisDrug Resistance NeoplasmCancer cellQuinazolinesCancer researchNeoplasm Recurrence LocalCarcinogenesisTranscription FactorsCell Death & Disease
researchProduct

Recurrent wheezing during the first 3 years of life in a birth cohort of moderate-to-late preterm infants.

2019

Background Data addressing short- and long-term respiratory morbidity in moderate-late preterm infants are limited. We aim to determine the incidence of recurrent wheezing and associated risk and protective factors in these infants during the first 3 years of life. Methods Prospective, multicenter birth cohort study of infants born at 32+0 to 35+0 weeks' gestation and followed for 3 years to assess the incidence of physician-diagnosed recurrent wheezing. Allergen sensitization and pulmonary function were also studied. We used multivariate mixed-effects models to identify risk factors associated with recurrent wheezing. Results A total of 977 preterm infants were enrolled. Rates of recurrent…

PalivizumabMalePediatricsmedicine.medical_specialtymedicine.medical_treatmentImmunologyPulmonary function testingCohort Studies03 medical and health sciences0302 clinical medicineRecurrencemedicineHypersensitivityImmunology and AllergyHumans030212 general & internal medicineAsthmaRespiratory SoundsMechanical ventilationPregnancybusiness.industryIncidence (epidemiology)IncidenceInfant NewbornInfantAtopic dermatitisAllergensmedicine.diseaseAsthmaRespiratory Function Tests030228 respiratory systemChild PreschoolPediatrics Perinatology and Child HealthGestationFemaleImmunizationbusinessInfant Prematuremedicine.drugFollow-Up StudiesPediatric allergy and immunology : official publication of the European Society of Pediatric Allergy and ImmunologyREFERENCES
researchProduct

Reoperation for persistent or recurrent secondary hyperparathyroidism. Surgical treatment of renal hyperparathyroidism

2017

Background: Secondary hyperparathyroidism is a common acquired disorder seen in chronic renal failure. Its pathophysiology is mainly due to hyperphosphatemia and vitamin D deficiency and resistance. When medical treatment fails, subtotal and total parathyroidectomy with autotransplantation are the standard procedures, although both are associated with high recurrence rates. Methods and Results: 4 patients experienced persistence and 9 relapse. The first 4 were subjected to reoperation after 6 months for the persistence of symptoms due to the finding of a supernumerary adenomatous gland while the remaining patients at the reoperation showed in 5 cases 2 more glands in over thymic position, a…

ParathyroidectomyReoperationrecurrent hyperparathyroidismRecurrenceRenal Dialysispersistent hyperparathyroidismsubtotal parathyroidectomyHumansKidney Failure ChronicCase ReportHyperparathyroidism Secondaryintraoperative parathyroid hormone measurementRetrospective StudiesActa bio-medica : Atenei Parmensis
researchProduct